TARSUS PHARMACEUTICALS INC's ticker is TARS and the CUSIP is 87650L103. A total of 117 filers reported holding TARSUS PHARMACEUTICALS INC in Q4 2023. The put-call ratio across all filers is 0.16 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $170,000 | +42.9% | 6,245 | +91.0% | 0.00% | – |
| Q1 2024 | $119,000 | -55.4% | 3,270 | -75.3% | 0.00% | – |
| Q4 2023 | $267,000 | +140.5% | 13,214 | +110.3% | 0.00% | – |
| Q3 2023 | $111,000 | +122.0% | 6,283 | +123.0% | 0.00% | – |
| Q2 2023 | $50,000 | +212.5% | 2,817 | +122.0% | 0.00% | – |
| Q1 2023 | $16,000 | -62.8% | 1,269 | -57.0% | 0.00% | – |
| Q4 2022 | $43,000 | +437.5% | 2,953 | +566.6% | 0.00% | – |
| Q3 2022 | $8,000 | +100.0% | 443 | +37.6% | 0.00% | – |
| Q2 2022 | $4,000 | -69.2% | 322 | -56.3% | 0.00% | – |
| Q1 2022 | $13,000 | -73.5% | 737 | -65.7% | 0.00% | – |
| Q4 2021 | $49,000 | +145.0% | 2,147 | +132.1% | 0.00% | – |
| Q3 2021 | $20,000 | +17.6% | 925 | +60.3% | 0.00% | – |
| Q2 2021 | $17,000 | -64.6% | 577 | -60.7% | 0.00% | – |
| Q1 2021 | $48,000 | +41.2% | 1,470 | +78.2% | 0.00% | – |
| Q4 2020 | $34,000 | – | 825 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 2,089,856 | $35,778,000 | 4.39% |
| Vivo Capital, LLC | 2,262,200 | $38,729,000 | 4.28% |
| Cormorant Asset Management, LP | 1,971,422 | $33,751,000 | 2.36% |
| Frazier Life Sciences Management, L.P. | 1,787,527 | $30,602,000 | 2.36% |
| Sands Capital Ventures, LLC | 260,000 | $4,451,000 | 1.29% |
| COWEN AND COMPANY, LLC | 522,329 | $8,942,000 | 0.86% |
| RTW INVESTMENTS, LP | 2,023,179 | $34,637,000 | 0.80% |
| Perceptive Advisors | 1,296,416 | $22,194,000 | 0.64% |
| Ghost Tree Capital, LLC | 120,000 | $2,054,000 | 0.58% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 1,324,214 | $22,671,000 | 0.45% |